Elena Strocchi | Università di Bologna (original) (raw)
Papers by Elena Strocchi
Uso del QPCS con matricole universitarie (PLS–Chimica Unibo) dall'a.a. 2018-19, con ipotesi d... more Uso del QPCS con matricole universitarie (PLS–Chimica Unibo) dall'a.a. 2018-19, con ipotesi di partenza: lo sviluppo dell'autodirezione nell'apprendimento favorisce la continuità negli studi. Il percorso è in tre fasi: a) somministrazione del QPCS a matricole chimiche (N=436); b) restituzione in presenza dei risultati; c) tutorato a 44 studenti. Riflessioni: modalità di restituzione, uso dei risultati QPCS, reazioni degli studenti. Obiettivo: costruire un quadro concettuale per futura ricerca.
Journal of Clinical Oncology, 2006
12003 Background: Cape is an efficient oral prodrug of 5FU in MBC and CRC. Unexpected severe toxi... more 12003 Background: Cape is an efficient oral prodrug of 5FU in MBC and CRC. Unexpected severe toxicity in older patients (pts) was reported after standard dose of 2500mg/sm/day. About 70% of drug and metabolites are excreted with the urine and a 25% reduction of the dose is recommended if the pt has a creatinine clearance (CrCl) <50ml/min. However no prospective study has been done on Cape PK in the elderly pts. Methods: Between Oct 2004 and Nov 2005, 21 pts with MBC or CRC and age ≥70yrs or ≤60yrs who received Cape (1000 mg/sm bid for 14 days every 21 days) entered the study after giving signed informed consent. CrCl was calculated according to the Cockcroft-Gault method. Patient characteristics: 15 elderly pts (median 78 range71–84yrs), 6 younger pts (median 50.5 range 43–57yrs); 9 (42.9%) males and 12 (57.1%) females; median KPS 90 (range 70–100); 8 MBC pts (38%), 13 CRC pts (62%). Blood samples were taken on the first day of treatment at time 0 and at 0.25,0.5,1,2,3,4,5,6,8 hr...
ICERI Proceedings, 2019
\uabMasterLab - Challenge the Science\ubb is a serious video-game designed to help high school st... more \uabMasterLab - Challenge the Science\ubb is a serious video-game designed to help high school students to self-evaluate the adequacy of their educational background in view of a University degree program in Chemistry. The project is developed by a joint working group at the Universities of Bologna and Parma together with a professional videogame producer, in the framework and with the funding of the Italian Scientific Degrees Plan (PLS) \u2013 Chemistry. \uabMasterLab - Challenge the Science\ubb is conceived as a Role Playing Game where the student/player moves throughout different rooms, each containing a different puzzle to solve. The puzzles consist in basic chemistry, mathematics and physics problems at a high school difficulty level and require virtual laboratory operations, measurements and calculations. The puzzles are built up and "gamified" in a modular manner, so they can be quickly written by the experts involved in the project. The game map develops randomly in order to offer to players different kind of problems in each game session. The project is easily expandable, by adding new puzzles, rooms, graphic elements, etc. and could be also extended to other scientific areas. When the player decides to end the game session, she/he will get a score (i.e. a piece of the \u201cseal of science\u201d) depending on the type of skill she/he has demonstrated. Game data will be recorded (according to privacy), in order to obtain accurate and detailed statistics regarding the knowledge of the individual topics useful also for high school teachers. \uabMasterLab - Challenge the Science\ubb will be free, playable both on mobile devices (smartphone or tablet) and PC/MAC and easily accessible without the need of installation. A collaboration with a Science of Education Department was activated to provide the video-game with validity in term of pedagogical content and approach, to evaluate the effectiveness of the project in term of self-evaluation and to prevent discouraging effects on low score students. A preliminary beta-1 version of the video-game will be presented on the next November to the network of National Scientific Degrees Plan (PLS) \u2013 Chemistry. The official release will be delivered and tested in schools starting from spring 2020
ChemMedChem, Jan 6, 2018
A novel and straightforward synthesis of highly substituted isoquinoline-5,8-dione fused tricycli... more A novel and straightforward synthesis of highly substituted isoquinoline-5,8-dione fused tricyclic pyrazoles is reported. The key step of the synthetic sequence is a regioselective, Ag CO promoted, 1,3-dipolar cycloaddition of C-heteroaryl-N-aryl nitrilimines and substituted isoquinoline-5,8-diones. The broad functional group tolerability and mild reaction conditions were found to be suitable for the preparation of a small library of compounds. These scaffolds were designed to interact with multiple biological residues, and two of them, after brief synthetic elaborations, were analyzed by molecular docking studies as potential anticancer drugs. In vitro studies confirmed the potent anticancer effects, showing promising IC values as low as 2.5 μm against three different glioblastoma cell lines. Their cytotoxic activity was finally positively correlated to their ability to inhibit PI3K/mTOR kinases, which are responsible for the regulation of diverse cellular processes in human cancer...
Giornale italiano di chemioterapia
Drugs under experimental and clinical research, 1985
The high hepatic clearance of the new doxorubicin analogue epirubicin (4'-epidoxorubicin, epi... more The high hepatic clearance of the new doxorubicin analogue epirubicin (4'-epidoxorubicin, epiDX) suggests a possible use of this drug in local and regional therapy where a first pass through the liver is required before the drug can reach systemic circulation. EpiDX pharmacokinetics was followed in advanced cancer patients with liver metastases or a primary tumour after single bolus administration in the hepatic artery, through a surgically implanted catheter and subcutaneous access port. The first-pass effect through the liver was appreciable and only a relatively low fraction of the drug reached systemic circulation. Mild leucopenia and alopecia were observed only in a patient with a hepatopulmonary shunt; this subject was actually exposed to higher epiDX plasma levels. Low intraperitoneal doses of epiDX were administered in a weekly schedule to advanced cancer patients with peritoneal metastases and ascites. Drug concentrations were monitored in the ascitic effusion and in pl...
Minerva ginecologica, 1982
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1984
Ten advanced cancer patients (both with hormone-sensitive and non-hormone sensitive tumors) were ... more Ten advanced cancer patients (both with hormone-sensitive and non-hormone sensitive tumors) were treated with high dose medroxyprogesterone acetate (MAP, greater than 500 mg/day). We determined body weight, lean body mass, blood pressure, sodium blood level, urinary excretion, and exchangeable sodium pool by the 22Na method before and after treatment. These data seem to exclude a fluid retentive effect for high-dose MAP.
Drugs under experimental and clinical research, 1985
Plasma and whole blood pharmacokinetics of epirubicin (4'-epidoxorubicin, epiDX), a new doxor... more Plasma and whole blood pharmacokinetics of epirubicin (4'-epidoxorubicin, epiDX), a new doxorubicin (DX) analogue with an improved spectrum of activity and lower toxicity, were investigated in advanced cancer patients after i.v. bolus administration. Drug decay is triphasic, with a long terminal half-life. Plasma and blood levels of the C-13 reduced epiDX metabolite, epirubicinol (epiDXol), are lower than those of the parent compound. Glucuronides of epiDX and epiDXol are also present in plasma, bile and urine; similar compounds are not described in the literature among the metabolites of DX. EpiDX plasma clearance is consistently higher and mean residence time lower than the corresponding DX parameters, thus indicating a more efficient disposition of the new drug. This behaviour is also reflected in a faster elimination of epiDXol with respect to the corresponding Dx metabolite, doxorubicinol. After an initial induction period, epiDX concentration is higher in whole blood than ...
European journal of cancer, 1980
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1986
A comparison has been made between the absorption of oral medroxyprogesterone acetate (MPA) in an... more A comparison has been made between the absorption of oral medroxyprogesterone acetate (MPA) in an aqueous suspension preparation and in syrup form. Plasma drug profiles were measured after a single administration of the two formulations in 17 advanced cancer patients. On average the standard form (aqueous suspension) gave peak levels which were lower than the syrup mixture. However, the wide intersubject spread in MPA plasma levels observed in both groups did not allow any statistical significance to be assigned to this difference.
Journal of Steroid Biochemistry, 1986
Advances in Experimental Medicine and Biology, 1988
European Journal of Cancer, 1993
Cancer Chemotherapy and Pharmacology, 1992
administration than after i.v. treatment in proportion to the AUC of IDA (i.v.: AUC-IDAol/AUC-IDA... more administration than after i.v. treatment in proportion to the AUC of IDA (i.v.: AUC-IDAol/AUC-IDA, 2.4-18.9; p.o.: AUC-IDAol/AUC-IDA, 4.1-21.4). Following oral dosing, a substantial amount of 4-demethoxydannomycinone (AG1) was found in 11/21 patients. No AG1 was detected after i.v. treatment, nor was the corresponding aglycone derived from IDAol found after p.o. or i.v. administration. IDA bioavailability, computed as the ratio of the dose-corrected AUC after p. o: and i.v. treatments in the same patient, was in the 25.2%-35.7% range for groups N, L, and R. Group LR showed a significantly reduced IDA bioavailability (15.7% +5.2%). However, a better description of the actual bioavailability was obtained by taking into account the AUCs of both IDA and IDAol after i.v. and p.o. administration and the relative potency of the two compounds.
Cancer Chemotherapy and Pharmacology, 1995
The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets," ... more The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets," was investigated in a single-dose, open-label, balancedfor-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.
Uso del QPCS con matricole universitarie (PLS–Chimica Unibo) dall'a.a. 2018-19, con ipotesi d... more Uso del QPCS con matricole universitarie (PLS–Chimica Unibo) dall'a.a. 2018-19, con ipotesi di partenza: lo sviluppo dell'autodirezione nell'apprendimento favorisce la continuità negli studi. Il percorso è in tre fasi: a) somministrazione del QPCS a matricole chimiche (N=436); b) restituzione in presenza dei risultati; c) tutorato a 44 studenti. Riflessioni: modalità di restituzione, uso dei risultati QPCS, reazioni degli studenti. Obiettivo: costruire un quadro concettuale per futura ricerca.
Journal of Clinical Oncology, 2006
12003 Background: Cape is an efficient oral prodrug of 5FU in MBC and CRC. Unexpected severe toxi... more 12003 Background: Cape is an efficient oral prodrug of 5FU in MBC and CRC. Unexpected severe toxicity in older patients (pts) was reported after standard dose of 2500mg/sm/day. About 70% of drug and metabolites are excreted with the urine and a 25% reduction of the dose is recommended if the pt has a creatinine clearance (CrCl) <50ml/min. However no prospective study has been done on Cape PK in the elderly pts. Methods: Between Oct 2004 and Nov 2005, 21 pts with MBC or CRC and age ≥70yrs or ≤60yrs who received Cape (1000 mg/sm bid for 14 days every 21 days) entered the study after giving signed informed consent. CrCl was calculated according to the Cockcroft-Gault method. Patient characteristics: 15 elderly pts (median 78 range71–84yrs), 6 younger pts (median 50.5 range 43–57yrs); 9 (42.9%) males and 12 (57.1%) females; median KPS 90 (range 70–100); 8 MBC pts (38%), 13 CRC pts (62%). Blood samples were taken on the first day of treatment at time 0 and at 0.25,0.5,1,2,3,4,5,6,8 hr...
ICERI Proceedings, 2019
\uabMasterLab - Challenge the Science\ubb is a serious video-game designed to help high school st... more \uabMasterLab - Challenge the Science\ubb is a serious video-game designed to help high school students to self-evaluate the adequacy of their educational background in view of a University degree program in Chemistry. The project is developed by a joint working group at the Universities of Bologna and Parma together with a professional videogame producer, in the framework and with the funding of the Italian Scientific Degrees Plan (PLS) \u2013 Chemistry. \uabMasterLab - Challenge the Science\ubb is conceived as a Role Playing Game where the student/player moves throughout different rooms, each containing a different puzzle to solve. The puzzles consist in basic chemistry, mathematics and physics problems at a high school difficulty level and require virtual laboratory operations, measurements and calculations. The puzzles are built up and "gamified" in a modular manner, so they can be quickly written by the experts involved in the project. The game map develops randomly in order to offer to players different kind of problems in each game session. The project is easily expandable, by adding new puzzles, rooms, graphic elements, etc. and could be also extended to other scientific areas. When the player decides to end the game session, she/he will get a score (i.e. a piece of the \u201cseal of science\u201d) depending on the type of skill she/he has demonstrated. Game data will be recorded (according to privacy), in order to obtain accurate and detailed statistics regarding the knowledge of the individual topics useful also for high school teachers. \uabMasterLab - Challenge the Science\ubb will be free, playable both on mobile devices (smartphone or tablet) and PC/MAC and easily accessible without the need of installation. A collaboration with a Science of Education Department was activated to provide the video-game with validity in term of pedagogical content and approach, to evaluate the effectiveness of the project in term of self-evaluation and to prevent discouraging effects on low score students. A preliminary beta-1 version of the video-game will be presented on the next November to the network of National Scientific Degrees Plan (PLS) \u2013 Chemistry. The official release will be delivered and tested in schools starting from spring 2020
ChemMedChem, Jan 6, 2018
A novel and straightforward synthesis of highly substituted isoquinoline-5,8-dione fused tricycli... more A novel and straightforward synthesis of highly substituted isoquinoline-5,8-dione fused tricyclic pyrazoles is reported. The key step of the synthetic sequence is a regioselective, Ag CO promoted, 1,3-dipolar cycloaddition of C-heteroaryl-N-aryl nitrilimines and substituted isoquinoline-5,8-diones. The broad functional group tolerability and mild reaction conditions were found to be suitable for the preparation of a small library of compounds. These scaffolds were designed to interact with multiple biological residues, and two of them, after brief synthetic elaborations, were analyzed by molecular docking studies as potential anticancer drugs. In vitro studies confirmed the potent anticancer effects, showing promising IC values as low as 2.5 μm against three different glioblastoma cell lines. Their cytotoxic activity was finally positively correlated to their ability to inhibit PI3K/mTOR kinases, which are responsible for the regulation of diverse cellular processes in human cancer...
Giornale italiano di chemioterapia
Drugs under experimental and clinical research, 1985
The high hepatic clearance of the new doxorubicin analogue epirubicin (4'-epidoxorubicin, epi... more The high hepatic clearance of the new doxorubicin analogue epirubicin (4'-epidoxorubicin, epiDX) suggests a possible use of this drug in local and regional therapy where a first pass through the liver is required before the drug can reach systemic circulation. EpiDX pharmacokinetics was followed in advanced cancer patients with liver metastases or a primary tumour after single bolus administration in the hepatic artery, through a surgically implanted catheter and subcutaneous access port. The first-pass effect through the liver was appreciable and only a relatively low fraction of the drug reached systemic circulation. Mild leucopenia and alopecia were observed only in a patient with a hepatopulmonary shunt; this subject was actually exposed to higher epiDX plasma levels. Low intraperitoneal doses of epiDX were administered in a weekly schedule to advanced cancer patients with peritoneal metastases and ascites. Drug concentrations were monitored in the ascitic effusion and in pl...
Minerva ginecologica, 1982
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1984
Ten advanced cancer patients (both with hormone-sensitive and non-hormone sensitive tumors) were ... more Ten advanced cancer patients (both with hormone-sensitive and non-hormone sensitive tumors) were treated with high dose medroxyprogesterone acetate (MAP, greater than 500 mg/day). We determined body weight, lean body mass, blood pressure, sodium blood level, urinary excretion, and exchangeable sodium pool by the 22Na method before and after treatment. These data seem to exclude a fluid retentive effect for high-dose MAP.
Drugs under experimental and clinical research, 1985
Plasma and whole blood pharmacokinetics of epirubicin (4'-epidoxorubicin, epiDX), a new doxor... more Plasma and whole blood pharmacokinetics of epirubicin (4'-epidoxorubicin, epiDX), a new doxorubicin (DX) analogue with an improved spectrum of activity and lower toxicity, were investigated in advanced cancer patients after i.v. bolus administration. Drug decay is triphasic, with a long terminal half-life. Plasma and blood levels of the C-13 reduced epiDX metabolite, epirubicinol (epiDXol), are lower than those of the parent compound. Glucuronides of epiDX and epiDXol are also present in plasma, bile and urine; similar compounds are not described in the literature among the metabolites of DX. EpiDX plasma clearance is consistently higher and mean residence time lower than the corresponding DX parameters, thus indicating a more efficient disposition of the new drug. This behaviour is also reflected in a faster elimination of epiDXol with respect to the corresponding Dx metabolite, doxorubicinol. After an initial induction period, epiDX concentration is higher in whole blood than ...
European journal of cancer, 1980
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1986
A comparison has been made between the absorption of oral medroxyprogesterone acetate (MPA) in an... more A comparison has been made between the absorption of oral medroxyprogesterone acetate (MPA) in an aqueous suspension preparation and in syrup form. Plasma drug profiles were measured after a single administration of the two formulations in 17 advanced cancer patients. On average the standard form (aqueous suspension) gave peak levels which were lower than the syrup mixture. However, the wide intersubject spread in MPA plasma levels observed in both groups did not allow any statistical significance to be assigned to this difference.
Journal of Steroid Biochemistry, 1986
Advances in Experimental Medicine and Biology, 1988
European Journal of Cancer, 1993
Cancer Chemotherapy and Pharmacology, 1992
administration than after i.v. treatment in proportion to the AUC of IDA (i.v.: AUC-IDAol/AUC-IDA... more administration than after i.v. treatment in proportion to the AUC of IDA (i.v.: AUC-IDAol/AUC-IDA, 2.4-18.9; p.o.: AUC-IDAol/AUC-IDA, 4.1-21.4). Following oral dosing, a substantial amount of 4-demethoxydannomycinone (AG1) was found in 11/21 patients. No AG1 was detected after i.v. treatment, nor was the corresponding aglycone derived from IDAol found after p.o. or i.v. administration. IDA bioavailability, computed as the ratio of the dose-corrected AUC after p. o: and i.v. treatments in the same patient, was in the 25.2%-35.7% range for groups N, L, and R. Group LR showed a significantly reduced IDA bioavailability (15.7% +5.2%). However, a better description of the actual bioavailability was obtained by taking into account the AUCs of both IDA and IDAol after i.v. and p.o. administration and the relative potency of the two compounds.
Cancer Chemotherapy and Pharmacology, 1995
The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets," ... more The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets," was investigated in a single-dose, open-label, balancedfor-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.